Various teams, including the Institute of Microbiology of th...

Various teams, including the Institute of Microbiology of the Chinese Academy of Sciences, collaborated to develop a genetically-engineered monoclonal antibody, which has significant clinical application value for the treatment of COVID-19 antibodies, especially for various current variants.

Monoclonal antibody concept stocks rose, Junshi Biotech rose more than 10%, and Biotech followed suit.